Protein kinases: From targets to anti-cancer drugs

Annales pharmaceutiques françaises
F Cruzalegui

Abstract

Since the discovery of protein phosphorylation by E. Krebs and E. Fisher in the 1950s, protein kinases have been recognised as major players in cell signalling. Their implication in disease has been extensively validated in cancer, diabetes, cardiovascular disease and central nervous system pathologies. In the pharmaceutical industry, despite initial scepticism on the potential selectivity of adenosine tri-phosphate (ATP) competitor kinase inhibitors, knowledge of the human genome and three-dimensional structure of protein kinases has revealed structural and phylogenetic elements allowing differentiation amongst kinases. Consequently, we can distinguish today classes of kinases according to the selectivity profile of inhibitors in clinical development and drugs in the market. The abundance of available structural data for kinases and inhibitors allows us now to identify key interactions. However, new biding modes are identified leading to increase selectivity of particular compounds. Facing this mount of knowledge and experience on screening for small molecule inhibitors, industry faces several challenges: first, the choice of a kinase as target; secondly, how to obtain molecules with desired selectivity, potency and pharmacoki...Continue Reading

References

Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A J RossomandoT W Sturgill
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·T Hunter, B M Sefton
Sep 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·R C ParkerJ M Bishop
Oct 19, 2001·Medicinal Research Reviews·P TraxlerJ Zimmermann
Dec 10, 2002·Science·G ManningS Sudarsanam
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·James TsaiGideon Bollag
Dec 24, 2008·Nature Reviews. Cancer·Jianming ZhangNathanael S Gray
Mar 20, 2009·Quarterly Reviews of Biophysics·Louise N Johnson

❮ Previous
Next ❯

Citations

Mar 10, 2016·The Korean Journal of Parasitology·Zhaoshou YangHo-Woo Nam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.